Jason D. Katz

University of Arizona — United States

Medicine · Health Sciences

18h-index3.0kcitations60works4.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Liver physiology and pathology(17), PI3K/AKT/mTOR signaling in cancer(13), Chronic Lymphocytic Leukemia Research(6), Marine Sponges and Natural Products(5), Chemical Synthesis and Analysis(4)

Publications60 total

0217 Neuroticism Traits Predict Resilience to Executive Function Decline During Sleep Deprivation
SLEEP·2025Open Access
Correction to “Discovery of DFV890, a Potent Sulfonimidamide-Containing NLRP3 Inflammasome Inhibitor”
Journal of Medicinal Chemistry·2025
Discovery of DFV890, a Potent Sulfonimidamide-Containing NLRP3 Inflammasome Inhibitor
Journal of Medicinal Chemistry·2025· 19 cited
Breakdown of thalamocortical connectivity under sleep deprivation: implications for cognitive arousal and transient sleep states
SLEEP Advances·2025Open Access
Supplementary Methods, Table 1, Figure Legends 1-5 from MK-2461, a Novel Multitargeted Kinase Inhibitor, Preferentially Inhibits the Activated c-Met Receptor
2023Open Access
Supplementary Figure 5 from MK-2461, a Novel Multitargeted Kinase Inhibitor, Preferentially Inhibits the Activated c-Met Receptor
2023Open Access
Supplementary Figure 3 from MK-2461, a Novel Multitargeted Kinase Inhibitor, Preferentially Inhibits the Activated c-Met Receptor
2023Open Access
Supplementary Methods, Table 1, Figure Legends 1-5 from MK-2461, a Novel Multitargeted Kinase Inhibitor, Preferentially Inhibits the Activated c-Met Receptor
2023Open Access
Supplementary Figure 2 from MK-2461, a Novel Multitargeted Kinase Inhibitor, Preferentially Inhibits the Activated c-Met Receptor
2023Open Access
Supplementary Figure 1 from MK-2461, a Novel Multitargeted Kinase Inhibitor, Preferentially Inhibits the Activated c-Met Receptor
2023Open Access
Supplementary Figure 5 from MK-2461, a Novel Multitargeted Kinase Inhibitor, Preferentially Inhibits the Activated c-Met Receptor
2023Open Access
Supplementary Figure 3 from MK-2461, a Novel Multitargeted Kinase Inhibitor, Preferentially Inhibits the Activated c-Met Receptor
2023Open Access
Supplementary Figure 4 from MK-2461, a Novel Multitargeted Kinase Inhibitor, Preferentially Inhibits the Activated c-Met Receptor
2023Open Access
Data from MK-2461, a Novel Multitargeted Kinase Inhibitor, Preferentially Inhibits the Activated c-Met Receptor
2023Open Access
Supplementary Figure 4 from MK-2461, a Novel Multitargeted Kinase Inhibitor, Preferentially Inhibits the Activated c-Met Receptor
2023Open Access
Supplementary Figure 2 from MK-2461, a Novel Multitargeted Kinase Inhibitor, Preferentially Inhibits the Activated c-Met Receptor
2023Open Access
Data from MK-2461, a Novel Multitargeted Kinase Inhibitor, Preferentially Inhibits the Activated c-Met Receptor
2023Open Access
Supplementary Figure 1 from MK-2461, a Novel Multitargeted Kinase Inhibitor, Preferentially Inhibits the Activated c-Met Receptor
2023Open Access
Divergent and Regioselective Synthesis of Pyrazolo[1,5-<i>a</i>]pyridines and Imidazo[1,5-<i>a</i>]pyridines
Organic Letters·2021· 14 cited
Discovery of a new series of PI3K-δ inhibitors from Virtual Screening
Bioorganic & Medicinal Chemistry Letters·2021· 4 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

James P. Jewell(13), Alexander A. Szewczak(13), Christopher J. Dinsmore(13), Sujal V. Deshmukh(12), Bo‐Sheng Pan(11), Lenora J. Davis(11), Gaozhen Hang(11), Harold Hatch(11), Kaiko Kunii(11), Bart Lutterbach(11), Xianlu Qu(11), John F. Reilly(11), Qinwen Zeng(11), Grace K.Y. Chan(10), Mélissa Chénard(10), An Chi(10), W. Wayt Gibbs(10), Ilona Kariv(10), Cloud P. Paweletz(10), Nancy E. Kohl(10)